This is a cell death mechanism involved in the response to both standard AML therapeutics like cytarabine [75, 76] and FLT3 inhibitors [76, 77], as well as emerging treatment strategies like imetelstat [11] and eprenetapopt [78]. Here, FLT3 is linked to acute myeloid leukemia.